Dendreon (DNDN) Continues Volitle Action On Continued Concerns About a Possible Advisory Panel on Provenge
Tweet Send to a Friend
Shares of Dendreon Corp. (Nasdaq: DNDN) are coming off the highs after CNBC reported that an FDA official e-mailed them ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
